https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-07-19 / Int J Cancer 2017 11;141(9):1891-1900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-07-19 / Int J Cancer 2017 11;141(9):1891-19002017-07-19 00:00:002021-11-15 20:03:02Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / Neuro-oncology 2017 06;19(6):796-807
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / Neuro-oncology 2017 06;19(6):796-8072017-06-01 00:00:002019-02-15 08:36:06Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-24 / Neurol. Med. Chir. (Tokyo) 2017 Jul;57(7):321-330
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-24 / Neurol. Med. Chir. (Tokyo) 2017 Jul;57(7):321-3302017-05-24 00:00:002019-02-15 08:36:10Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-12 / Nat Rev Neurol 2017 Jun;13(6):363-374
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-12 / Nat Rev Neurol 2017 Jun;13(6):363-3742017-05-12 00:00:002019-02-15 08:47:30Vaccine-based immunotherapeutic approaches to gliomas and beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-12 / J Transl Med 2017 05;15(1):104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-12 / J Transl Med 2017 05;15(1):1042017-05-12 00:00:002019-02-15 08:47:31A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-27 / Sci Rep 2017 04;7(1):1217
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-27 / Sci Rep 2017 04;7(1):12172017-04-27 00:00:002021-11-15 20:07:45Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-2352017-04-22 00:00:002019-02-15 08:47:31Dendritic cell based vaccination strategy: an evolving paradigm
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-1909
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-19092017-04-15 00:00:002019-02-15 08:47:32Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-12 / Onco Targets Ther 2017;10:2097-2106
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-12 / Onco Targets Ther 2017;10:2097-21062017-04-12 00:00:002019-02-15 08:34:49Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-01 / Neurotherapeutics 2017 04;14(2):345-357
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-01 / Neurotherapeutics 2017 04;14(2):345-3572017-04-01 00:00:002019-07-01 06:51:35Tumor Vaccines for Malignant Gliomas